HeyJaredSneha S K
- Indexed articles, last 90 days
- 1
- Latest publication
- Sep 8, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Sep 8, 2026
Latest articles
Inhibrx's Combination Cancer Drug Shrinks Tumors in Mid-stage Head and Neck Cancer Study (opens the original)
Read excerpt
Sept 8 (Reuters) - Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer. • In a 68-patient trial for head and neck squamous cell carcinoma that has spread and is inoperable, the drug INBRX-106 combined with Keytruda shrank or eliminated tumors in 48.3% of patients, versus 26.5% for Keytruda alone. • The benefit was strongest in patients with HPV-positive disease, with tumors shri
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.